Suppr超能文献

硫代色满酮缩氨基硫脲类似物作为组织蛋白酶L抑制剂的合成及生化评价

Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.

作者信息

Song Jiangli, Jones Lindsay M, Kumar G D Kishore, Conner Elizabeth S, Bayeh Liela, Chavarria Gustavo E, Charlton-Sevcik Amanda K, Chen Shen-En, Chaplin David J, Trawick Mary Lynn, Pinney Kevin G

机构信息

Department of Chemistry and Biochemistry, Baylor University , One Bear Place #97348, Waco, Texas, 76798-7348 United States.

OXiGENE Inc. , 701 Gateway Boulevard, Suite 210, South San Francisco, California, 94080, United States.

出版信息

ACS Med Chem Lett. 2012 Apr 18;3(6):450-3. doi: 10.1021/ml200299g. eCollection 2012 Jun 14.

Abstract

A series of 36 thiosemicarbazone analogues containing the thiochromanone molecular scaffold functionalized primarily at the C-6 position were prepared by chemical synthesis and evaluated as inhibitors of cathepsins L and B. The most promising inhibitors from this group are selective for cathepsin L and demonstrate IC50 values in the low nanomolar range. In nearly all cases, the thiochromanone sulfide analogues show superior inhibition of cathepsin L as compared to their corresponding thiochromanone sulfone derivatives. Without exception, the compounds evaluated were inactive (IC50 > 10000 nM) against cathepsin B. The most potent inhibitor (IC50 = 46 nM) of cathepsin L proved to be the 6,7-difluoro analogue 4. This small library of compounds significantly expands the structure-activity relationship known for small molecule, nonpeptidic inhibitors of cathepsin L.

摘要

通过化学合成制备了一系列36种硫代色满酮类似物,这些类似物主要在C-6位进行了官能化,含有硫代色满酮分子骨架,并作为组织蛋白酶L和B的抑制剂进行了评估。该组中最有前景的抑制剂对组织蛋白酶L具有选择性,其IC50值在低纳摩尔范围内。几乎在所有情况下,硫代色满酮硫化物类似物对组织蛋白酶L的抑制作用均优于其相应的硫代色满酮砜衍生物。无一例外,所评估的化合物对组织蛋白酶B均无活性(IC50>10000 nM)。组织蛋白酶L的最有效抑制剂(IC50 = 46 nM)被证明是6,7-二氟类似物4。这个小分子化合物库显著扩展了已知的小分子、非肽类组织蛋白酶L抑制剂的构效关系。

相似文献

1
Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.
ACS Med Chem Lett. 2012 Apr 18;3(6):450-3. doi: 10.1021/ml200299g. eCollection 2012 Jun 14.
2
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.
Bioorg Med Chem. 2015 Nov 1;23(21):6974-92. doi: 10.1016/j.bmc.2015.09.036. Epub 2015 Sep 25.
3
Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.
Bioorg Med Chem Lett. 2013 May 1;23(9):2801-7. doi: 10.1016/j.bmcl.2012.12.025. Epub 2012 Dec 20.
4
Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L.
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. doi: 10.1016/j.bmcl.2010.09.026. Epub 2010 Sep 15.
5
Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.
Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9. doi: 10.1016/j.bmcl.2009.12.090. Epub 2010 Jan 6.
6
Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.
Bioorg Chem. 2013 Dec;51:24-30. doi: 10.1016/j.bioorg.2013.09.002. Epub 2013 Sep 16.
7
A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
J Med Chem. 2003 Aug 14;46(17):3709-27. doi: 10.1021/jm0301078.
8
Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases.
Biochemistry. 1996 Jun 25;35(25):8149-57. doi: 10.1021/bi952736s.
10
Discovery of selective and nonpeptidic cathepsin S inhibitors.
Bioorg Med Chem Lett. 2008 Jul 15;18(14):3959-62. doi: 10.1016/j.bmcl.2008.06.009. Epub 2008 Jun 10.

引用本文的文献

2
5-Nitrofuryl-Containing Thiosemicarbazone Gold(I) Compounds: Synthesis, Stability Studies, and Anticancer Activity.
Chempluschem. 2023 Dec;88(12):e202300115. doi: 10.1002/cplu.202300115. Epub 2023 May 16.
3
CO Electrolysis via Surface-Engineering Electrografted Pyridines on Silver Catalysts.
ACS Catal. 2022 Jul 1;12(13):7862-7876. doi: 10.1021/acscatal.2c01654. Epub 2022 Jun 17.
4
Synthesis and Evaluation of Novel 2,2-Dimethylthiochromanones as Anti-Leishmanial Agents.
Molecules. 2021 Apr 12;26(8):2209. doi: 10.3390/molecules26082209.
5
6
Cathepsin L secretion by host and neoplastic cells potentiates invasion.
Oncotarget. 2019 Sep 17;10(53):5560-5568. doi: 10.18632/oncotarget.27182.
7
Hydrazone Derivatives Enhance Antileishmanial Activity of Thiochroman-4-ones.
Molecules. 2017 Dec 29;23(1):70. doi: 10.3390/molecules23010070.
8
New chroman-4-one/thiochroman-4-one derivatives as potential anticancer agents.
Saudi Pharm J. 2017 Nov;25(7):1063-1072. doi: 10.1016/j.jsps.2017.04.040. Epub 2017 Apr 26.
9
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.
Bioorg Med Chem. 2015 Nov 1;23(21):6974-92. doi: 10.1016/j.bmc.2015.09.036. Epub 2015 Sep 25.
10
3-Cyano-3-aza-β-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins.
ACS Med Chem Lett. 2014 Aug 11;5(10):1076-81. doi: 10.1021/ml500238q. eCollection 2014 Oct 9.

本文引用的文献

1
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):527-35. doi: 10.1016/j.ejcb.2010.11.005. Epub 2010 Dec 30.
2
Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L.
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. doi: 10.1016/j.bmcl.2010.09.026. Epub 2010 Sep 15.
4
Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor.
Curr Top Med Chem. 2010;10(7):696-707. doi: 10.2174/156802610791113441.
5
Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.
Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9. doi: 10.1016/j.bmcl.2009.12.090. Epub 2010 Jan 6.
6
Cathepsin L, target in cancer treatment?
Life Sci. 2010 Feb 13;86(7-8):225-33. doi: 10.1016/j.lfs.2009.11.016. Epub 2009 Nov 30.
7
Structure-guided development of selective TbcatB inhibitors.
J Med Chem. 2009 Oct 22;52(20):6489-93. doi: 10.1021/jm900908p.
8
Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB.
Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5. doi: 10.1016/j.bmcl.2008.03.083. Epub 2008 Apr 8.
9
Cysteine cathepsin proteases as pharmacological targets in cancer.
Trends Pharmacol Sci. 2008 Jan;29(1):22-8. doi: 10.1016/j.tips.2007.10.011. Epub 2007 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验